Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
- PMID: 32016126
- PMCID: PMC6988836
- DOI: 10.1093/ofid/ofaa008
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
Abstract
Background: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk.
Methods: We retrospectively reviewed 10-year data for S. maltophilia bacteremia in hospitalized adults at our institution to determine the population at risk, sources of infection, common complications, antimicrobial susceptibility profiles, and clinical outcome trends over the past decade.
Results: Among the 98 patients analyzed, the most common source of infection was catheter-related (62, 63.3%). Most isolates (61, 65%) were resistant to ceftazidime; fewer were resistant to trimethoprim-sulfamethoxazole (TMP-SMX; 2, 2.1%) and levofloxacin (22, 23.4%). All-cause in-hospital mortality was 29.6% (29 patients). The highest mortality, 53.8%, was observed in pulmonary sources of bacteremia.
Conclusions: Although TMP-SMX continues to have reliable activity in our cohort, we noted resistance to TMP-SMX in patients with recent TMP-SMX exposure, including a case with developing resistance to TMP-SMX while on therapy.
Keywords: Stenotrophomonas; bacteremia; multidrug resistance.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Similar articles
-
Emerging importance of multidrug-resistant Stenotrophomonas maltophilia infections in neonatal intensive care unit in a tertiary center in Turkey.Pediatr Neonatol. 2024 Mar;65(2):183-187. doi: 10.1016/j.pedneo.2023.04.019. Epub 2023 Oct 20. Pediatr Neonatol. 2024. PMID: 37919104
-
Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan.J Microbiol Immunol Infect. 2022 Feb;55(1):107-113. doi: 10.1016/j.jmii.2020.12.012. Epub 2021 Jan 13. J Microbiol Immunol Infect. 2022. PMID: 33500210
-
Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot.Health Serv Res Manag Epidemiol. 2019 Aug 15;6:2333392819870774. doi: 10.1177/2333392819870774. eCollection 2019 Jan-Dec. Health Serv Res Manag Epidemiol. 2019. PMID: 31453265 Free PMC article.
-
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.Front Microbiol. 2015 Sep 2;6:893. doi: 10.3389/fmicb.2015.00893. eCollection 2015. Front Microbiol. 2015. PMID: 26388847 Free PMC article. Review.
-
Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen.Pharmacotherapy. 1997 Mar-Apr;17(2):293-301. Pharmacotherapy. 1997. PMID: 9085321 Review.
Cited by
-
Characterization of the novel cross-genus phage vB_SmaS_QH3 and evaluation of its antibacterial efficacy against Stenotrophomonas maltophilia.Front Microbiol. 2025 Apr 11;16:1570665. doi: 10.3389/fmicb.2025.1570665. eCollection 2025. Front Microbiol. 2025. PMID: 40291807 Free PMC article.
-
Efficacy in Galleria mellonella Larvae and Application Potential Assessment of a New Bacteriophage BUCT700 Extensively Lyse Stenotrophomonas maltophilia.Microbiol Spectr. 2023 Feb 14;11(1):e0403022. doi: 10.1128/spectrum.04030-22. Epub 2023 Jan 26. Microbiol Spectr. 2023. PMID: 36700630 Free PMC article.
-
Risk Factors for Mortality in Patients with Stenotrophomonas maltophilia Bloodstream Infections in Immunocompetent Patients.Infect Dis Clin Microbiol. 2022 Sep 26;4(3):178-184. doi: 10.36519/idcm.2022.173. eCollection 2022 Sep. Infect Dis Clin Microbiol. 2022. PMID: 38633400 Free PMC article.
-
Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals.Open Forum Infect Dis. 2022 Jan 17;9(2):ofab644. doi: 10.1093/ofid/ofab644. eCollection 2022 Feb. Open Forum Infect Dis. 2022. PMID: 35097154 Free PMC article.
-
Assessment of Dust, Chemical, Microbiological Pollutions and Microclimatic Parameters of Indoor Air in Sports Facilities.Int J Environ Res Public Health. 2023 Jan 14;20(2):1551. doi: 10.3390/ijerph20021551. Int J Environ Res Public Health. 2023. PMID: 36674305 Free PMC article.
References
-
- Hamdi A, Fida M, AbuSaleh O, Beam E. 1042. Stenotrophomans maltophilia bacteremia, a 10-year tertiary center experience. Open Forum Infect Dis 2018; 5(Suppl_1):S311–S.
-
- Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007; 45:1602–9. - PubMed
-
- Kim SH, Cho SY, Kang CI, et al. . Clinical predictors of Stenotrophomonas maltophilia bacteremia in adult patients with hematologic malignancy. Ann Hematol 2018; 97:343–50. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous